{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:51:33Z","timestamp":1793757093546,"version":"4.6.1"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Liaoning Province Science and Technology Plan Joint Program","award":["2024-MSLH-528"],"award-info":[{"award-number":["2024-MSLH-528"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00228-025-03912-9","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T21:31:50Z","timestamp":1759872710000},"page":"1773-1786","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Optimizing acid-related disease management: insights into potassium-competitive acid blockers and proton pump inhibitors"],"prefix":"10.1007","volume":"81","author":[{"given":"Huihui","family":"Shang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijie","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiumei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaifu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"issue":"1","key":"3912_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5056\/jnm18139","volume":"25","author":"H Mori","year":"2019","unstructured":"Mori H, Suzuki H (2019) Role of acid suppression in acid-related diseases: proton pump inhibitor and potassium-competitive acid blocker. J Neurogastroenterol Motil 25(1):6\u201314","journal-title":"J Neurogastroenterol Motil"},{"issue":"6","key":"3912_CR2","doi-asserted-by":"publisher","first-page":"e2563","DOI":"10.1210\/clinem\/dgac062","volume":"107","author":"PH Tseng","year":"2022","unstructured":"Tseng PH, Hung CS, Tu CH et al (2022) Association of incidence of acid-related upper gastrointestinal disorders with glycated hemoglobin level. J Clin Endocrinol Metab 107(6):e2563-2571","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"3912_CR3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1080\/17474124.2021.1984878","volume":"16","author":"V Savarino","year":"2022","unstructured":"Savarino V, Antonioli L, Fornai M et al (2022) An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders. Expert Rev Gastroenterol Hepatol 16(5):401\u2013410","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1","key":"3912_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/apt.17510","volume":"58","author":"C Scarpignato","year":"2023","unstructured":"Scarpignato C, Howden CW, Leifke E et al (2023) A translational pharmacokinetic\/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection. Aliment Pharmacol Ther 58(1):16\u201325","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"3912_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/1751-2980.12813","volume":"20","author":"C Liu","year":"2019","unstructured":"Liu C, Feng BC, Zhang Y et al (2019) The efficacy of vonoprazan for management of post-endoscopic submucosal dissection ulcers compared with proton pump inhibitors: a meta-analysis. J Dig Dis 20(10):503\u2013511","journal-title":"J Dig Dis"},{"issue":"3","key":"3912_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/87551225231166531","volume":"39","author":"E St Onge","year":"2023","unstructured":"St Onge E, Phillips B (2023) Vonoprazan: a new potassium-competitive acid blocker. J Pharm Technol 39(3):139\u2013146","journal-title":"J Pharm Technol"},{"key":"3912_CR7","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X17745776","volume":"11","author":"K Sugano","year":"2018","unstructured":"Sugano K (2018) Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Therap Adv Gastroenterol 11:1756283X17745776","journal-title":"Therap Adv Gastroenterol"},{"issue":"7","key":"3912_CR8","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/apt.13121","volume":"41","author":"H Jenkins","year":"2015","unstructured":"Jenkins H, Sakurai Y, Nishimura A et al (2015) Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 41(7):636\u2013648","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"3912_CR9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00535-022-01861-z","volume":"57","author":"K Iwakiri","year":"2022","unstructured":"Iwakiri K, Fujiwara Y, Manabe N et al (2022) Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J Gastroenterol 57(4):267\u2013285","journal-title":"J Gastroenterol"},{"issue":"11","key":"3912_CR10","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1080\/14656566.2017.1346087","volume":"18","author":"I Martinucci","year":"2017","unstructured":"Martinucci I, Blandizzi C, Bodini G et al (2017) Vonoprazan fumarate for the management of acid related diseases. Expert Opin Pharmacother 18(11):1145\u20131152","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"3912_CR11","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1358\/dot.2020.56.11.3202811","volume":"56","author":"J Mermelstein","year":"2020","unstructured":"Mermelstein J, Mermelstein AC, Chait MM (2020) Tegoprazan to treat gastroesophageal reflux disease. Drugs Today (Barc) 56(11):715\u2013721","journal-title":"Drugs Today (Barc)"},{"issue":"1","key":"3912_CR12","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5056\/jnm22104","volume":"29","author":"JS Kim","year":"2023","unstructured":"Kim JS, Seo SI, Kang SH et al (2023) Effects of tegoprazan versus esomeprazole on nighttime heartburn and sleep quality in gastroesophageal reflux disease: a multicenter double-blind randomized controlled trial. J Neurogastroenterol Motil 29(1):58\u201364","journal-title":"J Neurogastroenterol Motil"},{"issue":"8","key":"3912_CR13","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00228-023-03521-4","volume":"79","author":"A Ramani","year":"2023","unstructured":"Ramani A, Merchant A, Cash BD (2023) Review of the clinical development of fexuprazan for gastroesophageal reflux-related disease. Eur J Clin Pharmacol 79(8):1023\u20131029","journal-title":"Eur J Clin Pharmacol"},{"issue":"11\u201312","key":"3912_CR14","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1111\/apt.16131","volume":"52","author":"JG Hwang","year":"2020","unstructured":"Hwang JG, Jeon I, Park SA et al (2020) Pharmacodynamics and pharmacokinetics of DWP14012 (fexuprazan) in healthy subjects with different ethnicities. Aliment Pharmacol Ther 52(11\u201312):1648\u20131657","journal-title":"Aliment Pharmacol Ther"},{"key":"3912_CR15","doi-asserted-by":"publisher","first-page":"106578","DOI":"10.1016\/j.ejps.2023.106578","volume":"190","author":"S Zhou","year":"2023","unstructured":"Zhou S, Xie L, Zhou C et al (2023) Keverprazan, a novel potassium-competitive acid blocker: single ascending dose safety, tolerability, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Eur J Pharm Sci 190:106578","journal-title":"Eur J Pharm Sci"},{"issue":"12","key":"3912_CR16","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1111\/jgh.16017","volume":"37","author":"DM Simadibrata","year":"2022","unstructured":"Simadibrata DM, Syam AF, Lee YY (2022) A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: a systematic review and meta-analysis. J Gastroenterol Hepatol 37(12):2217\u20132228","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"3912_CR17","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/apt.15062","volume":"49","author":"T Oshima","year":"2019","unstructured":"Oshima T, Arai E, Taki M et al (2019) Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis. Aliment Pharmacol Ther 49(2):140\u2013146","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"3912_CR18","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.7314\/APJCP.2015.16.4.1315","volume":"16","author":"T Hagiwara","year":"2015","unstructured":"Hagiwara T, Mukaisho K, Nakayama T et al (2015) Proton pump inhibitors and helicobacter pylori-associated pathogenesis. Asian Pac J Cancer Prev 16(4):1315\u20131319","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"3912_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5009\/gnl15502","volume":"11","author":"DS Strand","year":"2017","unstructured":"Strand DS, Kim D, Peura DA (2017) 25 years of proton pump inhibitors: a comprehensive review. Gut Liver 11(1):27\u201337","journal-title":"Gut Liver"},{"issue":"11\u201312","key":"3912_CR20","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/apt.13414","volume":"42","author":"DR Scott","year":"2015","unstructured":"Scott DR, Munson KB, Marcus EA et al (2015) The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+-ATPase. Aliment Pharmacol Ther 42(11\u201312):1315\u20131326","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"3912_CR21","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s10620-017-4866-6","volume":"63","author":"X Yang","year":"2018","unstructured":"Yang X, Li Y, Sun Y et al (2018) Vonoprazan: a novel and potent alternative in the treatment of acid-related diseases. Dig Dis Sci 63(2):302\u2013311","journal-title":"Dig Dis Sci"},{"issue":"3","key":"3912_CR22","doi-asserted-by":"publisher","first-page":"334","DOI":"10.5056\/jnm18029","volume":"24","author":"T Oshima","year":"2018","unstructured":"Oshima T, Miwa H (2018) Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases. J Neurogastroenterol Motil 24(3):334\u2013344","journal-title":"J Neurogastroenterol Motil"},{"issue":"2","key":"3912_CR23","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/cpdd.1009","volume":"11","author":"DJ Mulford","year":"2022","unstructured":"Mulford DJ, Leifke E, Hibberd M et al (2022) The effect of food on the pharmacokinetics of the potassium-competitive acid blocker vonoprazan. Clin Pharmacol Drug Dev 11(2):278\u2013284","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"6","key":"3912_CR24","doi-asserted-by":"publisher","first-page":"799","DOI":"10.5009\/gnl20242","volume":"15","author":"S Sue","year":"2021","unstructured":"Sue S, Maeda S (2021) Is a potassium-competitive acid blocker truly superior to proton pump inhibitors in terms of Helicobacter pylori eradication? Gut Liver 15(6):799\u2013810","journal-title":"Gut Liver"},{"issue":"2","key":"3912_CR25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2169\/internalmedicine.2521-18","volume":"59","author":"S Kiyotoki","year":"2020","unstructured":"Kiyotoki S, Nishikawa J, Sakaida I (2020) Efficacy of vonoprazan for Helicobacter pylori eradication. Intern Med 59(2):153\u2013161","journal-title":"Intern Med"},{"key":"3912_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.pharmthera.2016.08.001","volume":"168","author":"N Inatomi","year":"2016","unstructured":"Inatomi N, Matsukawa J, Sakurai Y et al (2016) Potassium-competitive acid blockers: advanced therapeutic option for acid-related diseases. Pharmacol Ther 168:12\u201322","journal-title":"Pharmacol Ther"},{"issue":"2","key":"3912_CR27","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/cpt.1973","volume":"109","author":"MR Botton","year":"2021","unstructured":"Botton MR, Whirl-Carrillo M, Del Tredici AL et al (2021) Pharmvar genefocus: CYP2C19. Clin Pharmacol Ther 109(2):352\u2013366","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"3912_CR28","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/MOG.0000000000000543","volume":"35","author":"C Scarpignato","year":"2019","unstructured":"Scarpignato C, Hunt RH (2019) The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Curr Opin Gastroenterol 35(4):344\u2013355","journal-title":"Curr Opin Gastroenterol"},{"issue":"8","key":"3912_CR29","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.clinthera.2021.06.007","volume":"43","author":"S Han","year":"2021","unstructured":"Han S, Choi HY, Kim YH et al (2021) Effect of food on the pharmacokinetics and pharmacodynamics of a single oral dose of tegoprazan. Clin Ther 43(8):1371\u20131380","journal-title":"Clin Ther"},{"issue":"7","key":"3912_CR30","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/apt.16295","volume":"53","author":"Y Abdel-Aziz","year":"2021","unstructured":"Abdel-Aziz Y, Metz DC, Howden CW (2021) Review article: potassium-competitive acid blockers for the treatment of acid-related disorders. Aliment Pharmacol Ther 53(7):794\u2013809","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"3912_CR31","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/17425255.2024.2397433","volume":"21","author":"A Tietto","year":"2025","unstructured":"Tietto A, Faggin S, Scarpignato C et al (2025) Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Expert Opin Drug Metab Toxicol 21(1):53\u201368","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"3912_CR32","doi-asserted-by":"publisher","first-page":"884","DOI":"10.5009\/gnl220457","volume":"17","author":"GH Kim","year":"2023","unstructured":"Kim GH, Choi MG, Kim JI et al (2023) Efficacy and safety of fexuprazan in patients with acute or chronic gastritis. Gut Liver 17(6):884\u2013893","journal-title":"Gut Liver"},{"issue":"5","key":"3912_CR33","doi-asserted-by":"publisher","first-page":"607","DOI":"10.5009\/gnl14135","volume":"9","author":"Y Jo","year":"2015","unstructured":"Jo Y, Park E, Ahn SB et al (2015) A proton pump inhibitor\u2019s effect on bone metabolism mediated by osteoclast action in old age: a prospective randomized study. Gut Liver 9(5):607\u2013614","journal-title":"Gut Liver"},{"issue":"4","key":"3912_CR34","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40262-015-0326-7","volume":"55","author":"H Echizen","year":"2016","unstructured":"Echizen H (2016) The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 55(4):409\u2013418","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"3912_CR35","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1097\/MCG.0000000000002052","volume":"58","author":"Y Fang","year":"2024","unstructured":"Fang Y, Lou D, Zhou J et al (2024) Efficacy and safety of potassium-competitive acid blockers versus proton pump inhibitors in treating erosive esophagitis: a meta-analysis based on randomized controlled trials. J Clin Gastroenterol 58(9):841\u2013850","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"3912_CR36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2169\/internalmedicine.7325-21","volume":"61","author":"M Okamoto","year":"2022","unstructured":"Okamoto M, Wakunami Y, Hashimoto K (2022) Severe hypomagnesemia associated with the long-term use of the potassium-competitive acid blocker vonoprazan. Intern Med 61(1):119\u2013122","journal-title":"Intern Med"},{"issue":"2","key":"3912_CR37","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2169\/internalmedicine.7758-21","volume":"61","author":"M Aiba","year":"2022","unstructured":"Aiba M, Tsutsumi Y, Nagai J et al (2022) Convulsive seizure due to hypomagnesemia caused by short-term vonoprazan intake. Intern Med 61(2):237\u2013240","journal-title":"Intern Med"},{"issue":"12","key":"3912_CR38","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1080\/00365521.2022.2097893","volume":"57","author":"S Shinozaki","year":"2022","unstructured":"Shinozaki S, Osawa H, Miura Y et al (2022) Long-term changes in serum gastrin levels during standard dose vonoprazan therapy. Scand J Gastroenterol 57(12):1412\u20131416","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"3912_CR39","first-page":"294","volume":"115","author":"H Gong","year":"2023","unstructured":"Gong H, Han D, Liu S et al (2023) Adverse events of vonoprazan in the treatments of acid-related diseases: a systematic review and meta-analysis. Rev Esp Enferm Dig 115(6):294\u2013300","journal-title":"Rev Esp Enferm Dig"},{"issue":"10","key":"3912_CR40","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3390\/ph13100276","volume":"13","author":"M Miftahussurur","year":"2020","unstructured":"Miftahussurur M, Pratama Putra B, Yamaoka Y (2020) The potential benefits of vonoprazan as Helicobacter pylori infection therapy. Pharmaceuticals (Basel) 13(10):276","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"3912_CR41","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/jgf2.485","volume":"23","author":"K Kubo","year":"2021","unstructured":"Kubo K, Sakakibara T, Yonezawa K et al (2021) Vonoprazan-associated long QT syndrome. J Gen Fam Med 23(1):54\u201355","journal-title":"J Gen Fam Med"},{"issue":"7","key":"3912_CR42","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/apt.15185","volume":"49","author":"KJ Lee","year":"2019","unstructured":"Lee KJ, Son BK, Kim GH et al (2019) Randomised phase 3 trial: tegoprazan, a novel potassium- competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. Aliment Pharmacol Ther 49(7):864\u2013872","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"3912_CR43","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/apt.15865","volume":"52","author":"YK Cho","year":"2020","unstructured":"Cho YK, Choi MG, Choi SC et al (2020) Randomised clinical trial: tegoprazan, a novel potassium- competitive acid blocker, or lansoprazole in the treatment of gastric ulcer. Aliment Pharmacol Ther 52(5):789\u2013797","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"3912_CR44","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/apt.16477","volume":"54","author":"SH Kim","year":"2021","unstructured":"Kim SH, Cho KB, Chun HJ et al (2021) Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease. Aliment Pharmacol Ther 54(4):402\u2013411","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"3912_CR45","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4292\/wjgpt.v9.i7.63","volume":"9","author":"P Rawla","year":"2018","unstructured":"Rawla P, Sunkara T, Ofosu A et al (2018) Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors? World J Gastrointest Pharmacol Ther 9(7):63\u201368","journal-title":"World J Gastrointest Pharmacol Ther"},{"issue":"3","key":"3912_CR46","doi-asserted-by":"publisher","first-page":"e12977","DOI":"10.1111\/hel.12977","volume":"28","author":"JS Kim","year":"2023","unstructured":"Kim JS, Ko W, Chung JW et al (2023) Efficacy of tegoprazan-based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: a randomized, double-blind, active-controlled study. Helicobacter 28(3):e12977","journal-title":"Helicobacter"},{"issue":"4","key":"3912_CR47","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/jgh.16471","volume":"39","author":"Q Zhuang","year":"2024","unstructured":"Zhuang Q, Liao A, He Q et al (2024) The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double-blind, multicenter study. J Gastroenterol Hepatol 39(4):658\u2013666","journal-title":"J Gastroenterol Hepatol"},{"issue":"10","key":"3912_CR48","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1111\/cts.13598","volume":"16","author":"S Zhou","year":"2023","unstructured":"Zhou S, Xie L, Zhou C et al (2023) Keverprazan, a novel potassium competitive acid blocker: multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects. Clin Transl Sci 16(10):1911\u20131922","journal-title":"Clin Transl Sci"},{"issue":"7","key":"3912_CR49","doi-asserted-by":"publisher","first-page":"e00602","DOI":"10.14309\/ctg.0000000000000602","volume":"14","author":"ND Tan","year":"2023","unstructured":"Tan ND, Miao XP, Liao AJ et al (2023) Efficacy and safety of keverprazan compared with lansoprazole in the treatment of duodenal ulcer: a phase III, randomized, double-blind, multicenter trial. Clin Transl Gastroenterol 14(7):e00602","journal-title":"Clin Transl Gastroenterol"},{"issue":"8","key":"3912_CR50","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/apt.17444","volume":"57","author":"I Hwang","year":"2023","unstructured":"Hwang I, Lee S (2023) Editorial: Deja vu all over again - let the P-CAB wars begin. Authors\u2019 reply. Aliment Pharmacol Ther 57(8):914\u2013915","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"3912_CR51","doi-asserted-by":"publisher","first-page":"27","DOI":"10.14309\/ajg.0000000000001538","volume":"117","author":"PO Katz","year":"2022","unstructured":"Katz PO, Dunbar KB, Schnoll-Sussman FH et al (2022) ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 117(1):27\u201356","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"3912_CR52","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/apt.17255","volume":"57","author":"YK Cho","year":"2023","unstructured":"Cho YK, Kim JH, Kim HS et al (2023) Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis. Aliment Pharmacol Ther 57(1):72\u201380","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"3912_CR53","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/14740338.2023.2136163","volume":"22","author":"T Kawai","year":"2023","unstructured":"Kawai T, Suzuki C, Honda Y et al (2023) Long-term safety and effectiveness of vonoprazan for prevention of gastric and duodenal ulcer recurrence in patients on nonsteroidal anti-inflammatory drugs in Japan: a 12-month post-marketing surveillance study. Expert Opin Drug Saf 22(5):425\u2013431","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"3912_CR54","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3892\/br.2021.1408","volume":"14","author":"S Shinozaki","year":"2021","unstructured":"Shinozaki S, Osawa H, Hayashi Y et al (2021) Long-term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor-resistant gastroesophageal reflux disease. Biomed Rep 14(3):32","journal-title":"Biomed Rep"},{"issue":"2","key":"3912_CR55","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/apt.13461","volume":"43","author":"K Ashida","year":"2016","unstructured":"Ashida K, Sakurai Y, Hori T et al (2016) Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther 43(2):240\u2013251","journal-title":"Aliment Pharmacol Ther"},{"issue":"14","key":"3912_CR56","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.3748\/wjg.v24.i14.1550","volume":"24","author":"K Ashida","year":"2018","unstructured":"Ashida K, Iwakiri K, Hiramatsu N et al (2018) Maintenance for healed erosive esophagitis: phase III comparison of vonoprazan with lansoprazole. World J Gastroenterol 24(14):1550\u20131561","journal-title":"World J Gastroenterol"},{"issue":"6","key":"3912_CR57","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1136\/gutjnl-2017-314010","volume":"67","author":"Y Mizokami","year":"2018","unstructured":"Mizokami Y, Oda K, Funao N et al (2018) Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut 67(6):1042\u20131051","journal-title":"Gut"},{"issue":"1","key":"3912_CR58","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1159\/000484217","volume":"97","author":"Y Kojima","year":"2018","unstructured":"Kojima Y, Takeuchi T, Sanomura M et al (2018) Does the novel potassium-competitive acid blocker vonoprazan cause more hypergastrinemia than conventional proton pump inhibitors? A multicenter prospective cross-sectional study. Digestion 97(1):70\u201375","journal-title":"Digestion"},{"issue":"5","key":"3912_CR59","doi-asserted-by":"publisher","first-page":"283","DOI":"10.11622\/smedj.2022076","volume":"63","author":"S Shinozaki","year":"2022","unstructured":"Shinozaki S, Osawa H, Hayashi Y et al (2022) Changes in gastric morphology during long-term use of vonoprazan compared to proton pump inhibitors. Singapore Med J 63(5):283\u2013287","journal-title":"Singapore Med J"},{"issue":"6","key":"3912_CR60","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3892\/br.2022.1534","volume":"16","author":"S Shinozaki","year":"2022","unstructured":"Shinozaki S, Osawa H, Miura Y et al (2022) The effect of proton pump inhibitors and vonoprazan on the development of \u2018gastric mucosal redness.\u2019 Biomed Rep 16(6):51","journal-title":"Biomed Rep"},{"issue":"1","key":"3912_CR61","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12876-023-02772-w","volume":"23","author":"K Haruma","year":"2023","unstructured":"Haruma K, Kinoshita Y, Yao T et al (2023) Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis. BMC Gastroenterol 23(1):139","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"3912_CR62","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1053\/j.gastro.2022.09.041","volume":"164","author":"L Laine","year":"2023","unstructured":"Laine L, DeVault K, Katz P et al (2023) Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: a randomized trial. Gastroenterology 164(1):61\u201371","journal-title":"Gastroenterology"},{"issue":"8","key":"3912_CR63","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1097\/CM9.0000000000003068","volume":"137","author":"YL Xiao","year":"2024","unstructured":"Xiao YL, Qian JM, Zhang ST et al (2024) Vonoprazan 10 mg or 20 mg vs. lansoprazole 15 mg as maintenance therapy in Asian patients with healed erosive esophagitis: a randomized controlled trial. Chin Med J Engl 137(8):962\u2013971","journal-title":"Chin Med J Engl"},{"issue":"24","key":"3912_CR64","first-page":"00770","volume":"S1542\u20133565","author":"N Uemura","year":"2024","unstructured":"Uemura N, Kinoshita Y, Haruma K et al (2024Aug 27) Vonoprazan as a long-term maintenance treatment for erosive esophagitis: VISION, a 5-year, randomized, open-label study. Clin Gastroenterol Hepatol S1542\u20133565(24):00770\u201300775","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"3912_CR65","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1136\/gutjnl-2016-313589","volume":"67","author":"LH Eusebi","year":"2018","unstructured":"Eusebi LH, Ratnakumaran R, Yuan Y et al (2018) Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut 67(3):430\u2013440","journal-title":"Gut"},{"issue":"45","key":"3912_CR66","doi-asserted-by":"publisher","first-page":"6410","DOI":"10.3748\/wjg.v28.i45.6410","volume":"28","author":"TL Lu","year":"2022","unstructured":"Lu TL, Li SR, Zhang JM et al (2022) Meta-analysis on the epidemiology of gastroesophageal reflux disease in China. World J Gastroenterol 28(45):6410\u20136420","journal-title":"World J Gastroenterol"},{"issue":"6","key":"3912_CR67","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nrgastro.2013.50","volume":"10","author":"E Savarino","year":"2013","unstructured":"Savarino E, Zentilin P, Savarino V (2013) Nerd: an umbrella term including heterogeneous subpopulations. Nat Rev Gastroenterol Hepatol 10(6):371\u2013380","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"13","key":"3912_CR68","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1080\/14656566.2017.1361407","volume":"18","author":"E Savarino","year":"2017","unstructured":"Savarino E, Zentilin P, Marabotto E et al (2017) A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD). Expert Opin Pharmacother 18(13):1333\u20131343","journal-title":"Expert Opin Pharmacother"},{"issue":"16","key":"3912_CR69","first-page":"00178","volume":"S0016\u20135085","author":"Q Aziz","year":"2016","unstructured":"Aziz Q, Fass R, Gyawali CP et al (2016) Functional esophageal disorders. Gastroenterology S0016\u20135085(16):00178\u201300185","journal-title":"Gastroenterology"},{"issue":"10","key":"3912_CR70","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1080\/17474124.2023.2267435","volume":"17","author":"M Ribolsi","year":"2023","unstructured":"Ribolsi M, Savarino E (2023) Towards a better diagnosis of gastro esophageal reflux disease. Expert Rev Gastroenterol Hepatol 17(10):999\u20131010","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1","key":"3912_CR71","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12916-016-0718-z","volume":"14","author":"C Scarpignato","year":"2016","unstructured":"Scarpignato C, Gatta L, Zullo A et al (2016) Effective and safe proton pump inhibitor therapy in acid-related diseases - a position paper addressing benefits and potential harms of acid suppression. BMC Med 14(1):179","journal-title":"BMC Med"},{"issue":"2","key":"3912_CR72","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1365-2036.2005.02531.x","volume":"22","author":"R Fass","year":"2005","unstructured":"Fass R, Shapiro M, Dekel R et al (2005) Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease\u2013where next? Aliment Pharmacol Ther 22(2):79\u201394","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"3912_CR73","doi-asserted-by":"publisher","first-page":"e14075","DOI":"10.1111\/nmo.14075","volume":"33","author":"F Zerbib","year":"2021","unstructured":"Zerbib F, Bredenoord AJ, Fass R et al (2021) ESNM\/ANMS consensus paper: diagnosis and management of refractory gastro-esophageal reflux disease. Neurogastroenterol Motil 33(4):e14075","journal-title":"Neurogastroenterol Motil"},{"issue":"1","key":"3912_CR74","doi-asserted-by":"publisher","first-page":"5","DOI":"10.5056\/jnm21095","volume":"28","author":"SJ Kang","year":"2022","unstructured":"Kang SJ, Jung HK, Tae CH et al (2022) On-demand versus continuous maintenance treatment of gastroesophageal reflux disease with proton pump inhibitors: a systematic review and meta-analysis. J Neurogastroenterol Motil 28(1):5\u201314","journal-title":"J Neurogastroenterol Motil"},{"issue":"9","key":"3912_CR75","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1136\/gut.2008.175810","volume":"58","author":"E Savarino","year":"2009","unstructured":"Savarino E, Pohl D, Zentilin P et al (2009) Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut 58(9):1185\u20131191","journal-title":"Gut"},{"issue":"9","key":"3912_CR76","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/gutjnl-2011-301897","volume":"61","author":"D Sifrim","year":"2012","unstructured":"Sifrim D, Zerbib F (2012) Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut 61(9):1340\u20131354","journal-title":"Gut"},{"issue":"5","key":"3912_CR77","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/gut.40.5.587","volume":"40","author":"RG Watson","year":"1997","unstructured":"Watson RG, Tham TC, Johnston BT et al (1997) Double-blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux\u2013the \u201csensitive oesophagus.\u201d Gut 40(5):587\u2013590","journal-title":"Gut"},{"issue":"11","key":"3912_CR78","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1136\/gutjnl-2019-318260","volume":"68","author":"A Pauwels","year":"2019","unstructured":"Pauwels A, Boecxstaens V, Andrews CN et al (2019) How to select patients for antireflux surgery? The ICARUS guidelines (international consensus regarding preoperative examinations and clinical characteristics assessment to select adult patients for antireflux surgery). Gut 68(11):1928\u20131941","journal-title":"Gut"},{"key":"3912_CR79","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1159\/000456072","volume":"95","author":"S Hoshino","year":"2017","unstructured":"Hoshino S, Kawami N, Takenouchi N et al (2017) Efficacy of vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Digestion 95:156\u2013161","journal-title":"Digestion"},{"issue":"2","key":"3912_CR80","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1159\/000497775","volume":"101","author":"J Akiyama","year":"2020","unstructured":"Akiyama J, Hosaka H, Kuribayashi S et al (2020) Efficacy of vonoprazan, a novel potassium-competitive acid blocker, in patients with proton pump inhibitor-refractory acid reflux. Digestion 101(2):174\u2013183","journal-title":"Digestion"},{"issue":"11","key":"3912_CR81","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1038\/ajg.2011.179","volume":"107","author":"N Viazis","year":"2012","unstructured":"Viazis N, Keyoglou A, Kanellopoulos AK et al (2012) Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol 107(11):1662\u20131667","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"3912_CR82","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/nmo.12313","volume":"26","author":"MR Ostovaneh","year":"2014","unstructured":"Ostovaneh MR, Saeidi B, Hajifathalian K et al (2014) Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: double-blind placebo-controlled trial. Neurogastroenterol Motil 26(5):670\u2013678","journal-title":"Neurogastroenterol Motil"},{"issue":"1","key":"3912_CR83","doi-asserted-by":"publisher","first-page":"92","DOI":"10.5009\/gnl220050","volume":"17","author":"S Han","year":"2023","unstructured":"Han S, Choi HY, Kim YH et al (2023) Comparison of pharmacodynamics between tegoprazan and dexlansoprazole regarding nocturnal acid breakthrough: a randomized crossover study. Gut Liver 17(1):92\u201399","journal-title":"Gut Liver"},{"issue":"7","key":"3912_CR84","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1111\/bcp.15268","volume":"88","author":"E Yang","year":"2022","unstructured":"Yang E, Kim S, Kim B et al (2022) Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole. Br J Clin Pharmacol 88(7):3288\u20133296","journal-title":"Br J Clin Pharmacol"},{"key":"3912_CR85","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.2147\/DDDT.S306371","volume":"15","author":"V Savarino","year":"2021","unstructured":"Savarino V, Marabotto E, Zentilin P et al (2021) Pharmacological management of gastro-esophageal reflux disease: an update of the state-of-the-art. Drug Des Devel Ther 15:1609\u20131621","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"3912_CR86","doi-asserted-by":"publisher","first-page":"259","DOI":"10.5056\/jnm24024","volume":"30","author":"S Seo","year":"2024","unstructured":"Seo S, Jung HK, Gyawali CP et al (2024) Treatment response with potassium-competitive acid blockers based on clinical phenotypes of gastroesophageal reflux disease: a systematic literature review and meta-analysis. J Neurogastroenterol Motil 30(3):259\u2013271","journal-title":"J Neurogastroenterol Motil"},{"key":"3912_CR87","doi-asserted-by":"publisher","first-page":"175628482412515","DOI":"10.1177\/17562848241251567","volume":"17","author":"Y Liu","year":"2024","unstructured":"Liu Y, Gao Z, Hou X (2024) Potassium-competitive acid blockers and proton-pump inhibitors for healing of erosive esophagitis: a systematic review and network meta-analysis. Therap Adv Gastroenterol 17:17562848241251568","journal-title":"Therap Adv Gastroenterol"},{"issue":"5","key":"3912_CR88","doi-asserted-by":"publisher","first-page":"803","DOI":"10.14309\/ajg.0000000000002714","volume":"119","author":"Q Zhuang","year":"2024","unstructured":"Zhuang Q, Chen S, Zhou X et al (2024) Comparative efficacy of P-CAB vs proton pump inhibitors for grade C\/D esophagitis: a systematic review and network meta-analysis. Am J Gastroenterol 119(5):803\u2013813","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"3912_CR89","doi-asserted-by":"publisher","first-page":"e13053","DOI":"10.1002\/jgh3.13053","volume":"8","author":"DM Simadibrata","year":"2024","unstructured":"Simadibrata DM, Lesmana E, Pratama MIA et al (2024) A systematic review with meta-analysis: efficacy and safety of potassium-competitive acid blocker compared with proton pump inhibitor in the maintenance of healed erosive esophagitis. JGH Open 8(3):e13053","journal-title":"JGH Open"},{"issue":"6","key":"3912_CR90","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1053\/j.gastro.2024.06.038","volume":"167","author":"A Patel","year":"2024","unstructured":"Patel A, Laine L, Moayyedi P et al (2024) AGA clinical practice update on integrating potassium-competitive acid blockers into clinical practice: expert review. Gastroenterology 167(6):1228\u20131238","journal-title":"Gastroenterology"},{"issue":"19","key":"3912_CR91","doi-asserted-by":"publisher","first-page":"6116","DOI":"10.3390\/jcm12196116","volume":"12","author":"HK Jeon","year":"2023","unstructured":"Jeon HK, Kim GH, Cheon YI et al (2023) Efficacy of tegoprazan in patients with laryngopharyngeal reflux disease: a preliminary feasibility study. J Clin Med 12(19):6116","journal-title":"J Clin Med"},{"issue":"11","key":"3912_CR92","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.1007\/s00405-024-08877-6","volume":"281","author":"SI Kim","year":"2024","unstructured":"Kim SI, Lee YC, Cha W et al (2024) Efficacy and safety of fexuprazan in patients with symptoms and signs of laryngopharyngeal reflux disease: a randomized clinical trial. Eur Arch Otorhinolaryngol 281(11):5873\u20135883","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"2","key":"3912_CR93","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4168\/aair.2024.16.2.191","volume":"16","author":"S Zhong","year":"2024","unstructured":"Zhong S, Zhong M, Fang L et al (2024) Potassium-competitive acid blocker versus proton pump inhibitor: a pilot study on comparable efficacy in the treatment of gastroesophageal reflux-related cough. Allergy Asthma Immunol Res 16(2):191\u2013201","journal-title":"Allergy Asthma Immunol Res"},{"key":"3912_CR94","unstructured":"Kang N, Kang MG, Lee SE, et al. Fexuprazan versus esomeprazole in GERD-related chronic cough: results from a double-blind placebo-controlled trial. Poster presented at KAAACI (Korean Academy of Asthma, Allergy and Clinical Immunology); 2024 May 5\u20138; Seoul, South Korea. Seoul International Congress."},{"issue":"1","key":"3912_CR95","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00408-025-00815-5","volume":"203","author":"N Kang","year":"2025","unstructured":"Kang N, Kang MG, Lee SE et al (2025) Efficacy and safety of fexuprazan versus esomeprazole for gastroesophageal reflux disease-related chronic cough: a randomized, double-blind, active-controlled exploratory trial. Lung 203(1):59","journal-title":"Lung"},{"issue":"1","key":"3912_CR96","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12876-022-02130-2","volume":"22","author":"X Xie","year":"2022","unstructured":"Xie X, Ren K, Zhou Z et al (2022) The global, regional and national burden of peptic ulcer disease from 1990 to 2019: a population-based study. BMC Gastroenterol 22(1):58","journal-title":"BMC Gastroenterol"},{"issue":"11","key":"3912_CR97","doi-asserted-by":"publisher","first-page":"e00776","DOI":"10.14309\/ctg.0000000000000776","volume":"15","author":"Y Wang","year":"2024","unstructured":"Wang Y, Dai X, Zhang X (2024) Network meta-analysis of comparing different dosages of potassium-competitive acid blocker with proton-pump inhibitor in acid-related disorders. Clin Transl Gastroenterol 15(11):e00776","journal-title":"Clin Transl Gastroenterol"},{"issue":"6","key":"3912_CR98","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3390\/ph17060698","volume":"17","author":"M Ouyang","year":"2024","unstructured":"Ouyang M, Zou S, Cheng Q et al (2024) Comparative efficacy and safety of potassium-competitive acid blockers vs. proton pump inhibitors for peptic ulcer with or without Helicobacter pylori infection: a systematic review and network meta-analysis. Pharmaceuticals (Basel) 17(6):698","journal-title":"Pharmaceuticals (Basel)"},{"key":"3912_CR99","doi-asserted-by":"publisher","first-page":"100776","DOI":"10.1016\/j.curtheres.2025.100776","volume":"102","author":"IM Yoon","year":"2025","unstructured":"Yoon IM, Kim KY, Lee KH et al (2025) Efficacy of potassium-competitive acid blockers versus proton pump inhibitors for gastric ulcers: Bayesian and frequentist network meta-analysis with cross-inference through a quality management system. Curr Ther Res Clin Exp 102:100776","journal-title":"Curr Ther Res Clin Exp"},{"issue":"9","key":"3912_CR100","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.14309\/ctg.0000000000000754","volume":"15","author":"WX Wang","year":"2024","unstructured":"Wang WX, Li RJ, Li XF (2024) Efficacy and safety of potassium-competitive acid blockers vs proton pump inhibitors for peptic ulcer disease or postprocedural artificial ulcers: a systematic review and meta-analysis. Clin Transl Gastroenterol 15(9):e1","journal-title":"Clin Transl Gastroenterol"},{"key":"3912_CR101","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/CEG.S228352","volume":"13","author":"E Marabotto","year":"2020","unstructured":"Marabotto E, Ziola S, Savarino V et al (2020) Vonoprazan fumarate for the treatment of gastric ulcers: a short review on emerging data. Clin Exp Gastroenterol 13:99\u2013104","journal-title":"Clin Exp Gastroenterol"},{"issue":"2","key":"3912_CR102","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/MCG.0000000000001719","volume":"57","author":"P Katelaris","year":"2023","unstructured":"Katelaris P, Hunt R, Bazzoli F et al (2023) Helicobacter pylori world gastroenterology organization global guideline. J Clin Gastroenterol 57(2):111\u2013126","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"3912_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1523-5378.2009.00738.x","volume":"15","author":"M Asaka","year":"2010","unstructured":"Asaka M, Kato M, Takahashi S et al (2010) Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 15(1):1\u201320","journal-title":"Helicobacter"},{"issue":"12","key":"3912_CR104","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1136\/gutjnl-2020-322368","volume":"69","author":"JM Liou","year":"2020","unstructured":"Liou JM, Malfertheiner P, Lee YC et al (2020) Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut 69(12):2093\u20132112","journal-title":"Gut"},{"issue":"3","key":"3912_CR105","first-page":"1215","volume":"12","author":"Z Zhong","year":"2022","unstructured":"Zhong Z, Zhan B, Xu B et al (2022) Emphasizing the importance of successful eradication of Helicobacter pylori on initial treatment. Am J Cancer Res 12(3):1215\u20131221","journal-title":"Am J Cancer Res"},{"issue":"2","key":"3912_CR106","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1523-5378.2011.00828.x","volume":"16","author":"PI Hsu","year":"2011","unstructured":"Hsu PI, Wu DC, Wu JY et al (2011) Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 16(2):139\u2013145","journal-title":"Helicobacter"},{"issue":"1","key":"3912_CR107","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/j.gastro.2016.04.006","volume":"151","author":"CA Fallone","year":"2016","unstructured":"Fallone CA, Chiba N, van Zanten SV et al (2016) The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology 151(1):51\u201369","journal-title":"Gastroenterology"},{"issue":"5","key":"3912_CR108","doi-asserted-by":"publisher","first-page":"107320","DOI":"10.1016\/j.ijantimicag.2024.107320","volume":"64","author":"N Tan","year":"2024","unstructured":"Tan N, Wu H, Lan C et al (2024) The efficacy of keverprazan-based quadruple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind, multicentre trial. Int J Antimicrob Agents 64(5):107320","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"3912_CR109","doi-asserted-by":"publisher","first-page":"e12940","DOI":"10.1111\/hel.12940","volume":"28","author":"L Lu","year":"2023","unstructured":"Lu L, Wang Y, Ye J et al (2023) Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: a single-center, open-label, noninferiority, randomized controlled trial. Helicobacter 28(1):e12940","journal-title":"Helicobacter"},{"issue":"1","key":"3912_CR110","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/bcp.14934","volume":"88","author":"KY Huh","year":"2022","unstructured":"Huh KY, Chung H, Kim YK et al (2022) Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication. Br J Clin Pharmacol 88(1):138\u2013144","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"3912_CR111","doi-asserted-by":"publisher","first-page":"e70134","DOI":"10.1002\/jgh3.70134","volume":"9","author":"DM Simadibrata","year":"2025","unstructured":"Simadibrata DM, Lesmana E, Damara I et al (2025) Tegoprazan-containing versus proton pump inhibitor-containing therapy for first-line eradication of Helicobacter pylori: a meta-analysis of randomized controlled trials. JGH Open 9(3):e70134","journal-title":"JGH Open"},{"issue":"3","key":"3912_CR112","doi-asserted-by":"publisher","first-page":"283","DOI":"10.15403\/jgld.2014.1121.253.7hp","volume":"25","author":"H Noda","year":"2016","unstructured":"Noda H, Noguchi S, Yoshimine T et al (2016) A novel potassium-competitive acid blocker improves the efficacy of clarithromycin-containing 7-day triple therapy against Helicobacter pylori. J Gastrointestin Liver Dis 25(3):283\u2013288","journal-title":"J Gastrointestin Liver Dis"},{"issue":"3","key":"3912_CR113","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40265-023-01991-5","volume":"84","author":"M Shirley","year":"2024","unstructured":"Shirley M (2024) Vonoprazan: a review in Helicobacter pylori infection. Drugs 84(3):319\u2013327","journal-title":"Drugs"},{"issue":"10","key":"3912_CR114","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1111\/jgh.15939","volume":"37","author":"YS Jung","year":"2022","unstructured":"Jung YS, Kim S, Kim HY et al (2022) 7-day versus 14-day tegoprazan-based triple therapy to treat Helicobacter pylori infection: real-world evidence. J Gastroenterol Hepatol 37(10):1911\u20131918","journal-title":"J Gastroenterol Hepatol"},{"issue":"9","key":"3912_CR115","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3748\/wjg.v30.i9.1213","volume":"30","author":"JE Kanu","year":"2024","unstructured":"Kanu JE, Soldera J (2024) Treatment of Helicobacter pylori with potassium competitive acid blockers: a systematic review and meta-analysis. World J Gastroenterol 30(9):1213\u20131223","journal-title":"World J Gastroenterol"},{"key":"3912_CR116","doi-asserted-by":"publisher","first-page":"175628482513148","DOI":"10.1177\/17562848251314801","volume":"18","author":"T Jin","year":"2025","unstructured":"Jin T, Wu W, Zhang L et al (2025) The efficacy and safety of vonoprazan and tegoprazan in Helicobacter pylori eradication: a comprehensive systematic review and meta-analysis of randomized controlled trials. Therap Adv Gastroenterol 18:17562848251314800","journal-title":"Therap Adv Gastroenterol"},{"key":"3912_CR117","doi-asserted-by":"publisher","first-page":"175628482096624","DOI":"10.1177\/1756284820966247","volume":"13","author":"M Hojo","year":"2020","unstructured":"Hojo M, Asaoka D, Takeda T et al (2020) Randomized controlled study on the effects of triple therapy including vonoprazan or rabeprazole for the second-line treatment of Helicobacter pylori infection. Therap Adv Gastroenterol 13:1756284820966247","journal-title":"Therap Adv Gastroenterol"},{"issue":"11","key":"3912_CR118","first-page":"e48465","volume":"15","author":"A Shah","year":"2023","unstructured":"Shah A, Usman O, Zahra T et al (2023) Efficacy and safety of potassium-competitive acid blockers versus proton pump inhibitors as Helicobacter pylori eradication therapy: a meta-analysis of randomized clinical trials. Cureus 15(11):e48465","journal-title":"Cureus"},{"key":"3912_CR119","doi-asserted-by":"publisher","first-page":"100058","DOI":"10.1016\/j.clinsp.2022.100058","volume":"77","author":"M Zhang","year":"2022","unstructured":"Zhang M, Pang M, Zhang M (2022) Efficacy and safety of potassium-competitive acid blockers versus proton pump inhibitors as Helicobacter pylori eradication therapy: a meta-analysis of randomized clinical trials. Clinics 77:100058","journal-title":"Clinics"},{"issue":"9","key":"3912_CR120","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.3390\/jcm12093110","volume":"12","author":"T Furuta","year":"2023","unstructured":"Furuta T, Yamade M, Higuchi T et al (2023) Expectations for the dual therapy with vonoprazan and amoxicillin for the eradication of H. pylori. J Clin Med 12(9):3110","journal-title":"J Clin Med"},{"issue":"4","key":"3912_CR121","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3390\/microorganisms13040715","volume":"13","author":"CA Shih","year":"2025","unstructured":"Shih CA, Wu DC, Shie CB et al (2025) Dual therapies containing an antibiotic plus a proton pump inhibitor or vonoprazan for Helicobacter pylori infection: a systematic review. Microorganisms 13(4):715","journal-title":"Microorganisms"},{"issue":"5","key":"3912_CR122","doi-asserted-by":"publisher","first-page":"107331","DOI":"10.1016\/j.ijantimicag.2024.107331","volume":"64","author":"J Zhang","year":"2024","unstructured":"Zhang J, Zhang H, Zhu XJ et al (2024) Efficacy and safety of vonoprazan and high-dose amoxicillin dual therapy in eradicating Helicobacter pylori: a systematic review and meta-analysis. Int J Antimicrob Agents 64(5):107331","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"3912_CR123","doi-asserted-by":"publisher","first-page":"e12918","DOI":"10.1111\/hel.12918","volume":"27","author":"W Gao","year":"2022","unstructured":"Gao W, Teng G, Wang C et al (2022) Eradication rate and safety of a \u2033simplified rescue therapy\u2033: 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: a real-world, retrospective clinical study in China. Helicobacter 27(5):e12918","journal-title":"Helicobacter"},{"key":"3912_CR124","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2147\/CEOR.S297680","volume":"13","author":"K Tokunaga","year":"2021","unstructured":"Tokunaga K, Suzuki C, Hasegawa M et al (2021) Cost analysis in Helicobacter pylori eradication therapy based on a database of health insurance claims in Japan. Clinicoecon Outcomes Res 13:241\u2013250","journal-title":"Clinicoecon Outcomes Res"},{"issue":"4","key":"3912_CR125","doi-asserted-by":"publisher","first-page":"787","DOI":"10.14309\/ajg.0000000000003084","volume":"120","author":"T Rokkas","year":"2025","unstructured":"Rokkas T, Ekmektzoglou K, Niv Y et al (2025) Comparative efficacy and safety of potassium-competitive acid blocker-based dual, triple, and quadruple regimens for first-line Helicobacter pylori infection treatment: a systematic review and network meta-analysis. Am J Gastroenterol 120(4):787\u2013798","journal-title":"Am J Gastroenterol"},{"key":"3912_CR126","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327745","author":"P Malfertheiner","year":"2022","unstructured":"Malfertheiner P, Megraud F, Rokkas T et al (2022) Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report. Gut. https:\/\/doi.org\/10.1136\/gutjnl-2022-327745","journal-title":"Gut"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03912-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03912-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03912-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:01:44Z","timestamp":1764914504000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03912-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":126,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3912"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03912-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"13 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}